Axinn Protects Client Endo Pharmaceuticals Inc.’s Approval for Generic Valcyte®
March 11, 2015
Axinn, on behalf of client Endo Pharmaceuticals Inc., successfully defended the U.S. Food and Drug Administration’s final approval of Endo’s generic Valcyte® by securing summary judgment in favor of Endo and FDA. Plaintiff Ranbaxy Laboratories, Ltd. had sought an order reversing FDA’s approval of Endo’s generic Valcyte® product after FDA recently decided to revoke tentative approval of Ranbaxy’s generic Valcyte® ANDA and determined that Ranbaxy had forfeited its generic marketing exclusivity rights. Judge Beryl Howell of the United Stated District Court for the District of Columbia determined that FDA had acted within its authority.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
National Bar Association 100th Annual Convention and Exhibits
Sponsorship
Antitrust
Keeping Pace: Updates in Cartel Enforcement
Webinar
Antitrust
GCR Live: Law Leaders Europe 2025
Speaking Engagement
Antitrust
Navigating Compliance: How the 2025 Hart-Scott-Rodino Updates Are Impacting Businesses
Webinar
Antitrust
AHLA Annual Meeting 2025
Speaking Engagement
Antitrust
MBK | MSK Fellowship Summit 2025
Sponsorship
Antitrust
SABA North America Annual Conference 2025
Speaking Engagement
Antitrust
Axinn Attorneys Recognized by IAM Patent 1000
News
Intellectual Property
Intellectual Property and Antitrust
Byline Articles
Intellectual Property
Axinn Recognized by Legal 500 2025 U.S. Guide for Excellence in Antitrust and Litigation
Awards & Recognitions